Opinion|Videos|June 28, 2024
Dr Oliva on Addressing Challenges in Treating Lower-Risk MDS
Key opinion leaders address various challenges linked to lower-risk myelodysplastic syndromes, with a focus on cytopenias.
Advertisement
Episodes in this series
- Dr Garcia-Manero to Dr Oliva: What present challenges exist for treating patients with lower-risk MDS? Do not take to transplant. Challenge for other cytopenias—no drug for this. Remission of low-risk disease.
Advertisement
Related to this article
With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
Read on to see which data are poised to shape clinical discussions and decision-making in lung cancer at the 2026 ESMO Congress in Madrid, Spain.
New severe treatment-related adverse effects after discharge from lifileucel therapy were uncommon and emerged across several months.
Invikafusp alfa now holds fast track status across TMB-H solid tumors that progressed after prior therapy, including checkpoint inhibition.
Richard J. Bleicher, MD, FACS, has been selected to serve as Chair of the American College of Surgeons.
Patients with resected RCC given adjuvant durvalumab with or without tremelimumab described persistent low-grade toxicities as most disruptive to QOL.
The EMA's CHMP recommended approval of daraxonrasib for metastatic pancreatic adenocarcinoma after at least 1 prior systemic therapy.
VS-7375 produced a responses previously treated metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
SurVaxM Cancer Vaccine Shows Clinically Meaningful OS Signal in Newly Diagnosed Glioblastoma
2
CHMP Recommends Approval of Daraxonrasib for Previously Treated Metastatic Pancreatic Cancer
3
VS-7375 Elicits Responses in KRAS G12D–Mutated Pancreatic Cancer
4
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
5